1-(5-chlorothiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid | 688313-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-(5-chlorothiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid
• 英文别名: 1-(5-Chloro-thiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic Acid；1-[(5-chlorothiophen-2-yl)methyl]pyrrolo[2,3-c]pyridine-5-carboxylic acid
• CAS: 688313-63-5
• 化学式: C₁₃H₉ClN₂O₂S
• 分子量: 292.746
• InChiKey: AXQZGIOYEUJUCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(5-chlorothiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid 在 盐酸羟胺 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以33%的产率得到1-(5-chlorothiophen-2-ylmethyl)-N-hydroxy-1H-pyrrolo[2,3-c]pyridine-5-carboxamide
  参考文献：
  名称：

  Azaindole Hydroxamic Acids are Potent HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication. Recently, HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Herein, we report the discovery of azaindole carboxylic acids and azaindole hydroxamic acids as potent inhibitors of the HIV-1 IN enzyme and their structure-activity relationships. Several 4-fluorobenzyl substituted azaindole hydroxamic acids showed potent antiviral activities in cell-based assays and offered a structurally simple scaffold for the development of novel HIV-1 IN inhibitors.

  DOI：

  10.1021/jm900862n
• 作为产物：
  描述：

  ethyl 1-(5-chlorothiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 在 水 、 sodium hydroxide 、 柠檬酸 作用下， 以 甲醇 、 水 为溶剂， 反应 0.08h， 以68%的产率得到1-(5-chlorothiophen-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid
  参考文献：
  名称：

  Azaindole Hydroxamic Acids are Potent HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication. Recently, HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Herein, we report the discovery of azaindole carboxylic acids and azaindole hydroxamic acids as potent inhibitors of the HIV-1 IN enzyme and their structure-activity relationships. Several 4-fluorobenzyl substituted azaindole hydroxamic acids showed potent antiviral activities in cell-based assays and offered a structurally simple scaffold for the development of novel HIV-1 IN inhibitors.

  DOI：

  10.1021/jm900862n

文献信息

• HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040147547A1

  公开（公告）日：2004-07-29

  Bicyclic hydroxamate compounds represented by the Formula I: 1 are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

  描述了由公式I：1表示的双环羟肟化合物。这些双环羟肟化合物和含有这些化合物的组合物可用于抑制或调节HIV整合酶的酶活性，并用于治疗HIV介导的疾病和病状。
• HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE
  申请人：HU Qiyue

  公开号：US20080221154A1

  公开（公告）日：2008-09-11

  Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

  描述了由公式I表示的二环羟肟化合物。这些二环羟肟化合物和含有这些化合物的组合物可用于抑制或调节HIV整合酶的酶活性，并用于治疗HIV介导的疾病和病况。
• HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE
  申请人：Hu Qiyue

  公开号：US20070004768A1

  公开（公告）日：2007-01-04

  Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

  本文描述了由I式表示的二环羟肟类化合物。这些二环羟肟类化合物和含有这些化合物的组合物可用于抑制或调节HIV整合酶的酶活性，以及治疗HIV介导的疾病和病状。
• HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use
  申请人：Pfizer Inc

  公开号：US07368571B2

  公开（公告）日：2008-05-06

  Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

  本文描述了由公式I表示的自行车羟肟化合物。这些自行车羟肟化合物和含有这些化合物的组合物可用于抑制或调节HIV整合酶的酶活性，并用于治疗HIV介导的疾病和病况。
• US7135482B2
  申请人：——

  公开号：US7135482B2

  公开（公告）日：2006-11-14